Association between nesfatin-1 levels and metabolic improvements in severely obese patients who underwent biliopancreatic derivation with duodenal switch.
Nesfatin-1 is a neuroendocrine peptide with potent anorexigenic activity in rodents. The potential role of nesfatin-1 on the regulation of energy balance, metabolic functions and inflammation is currently debated in obese humans. In the present study, nesfatin-1 fluctuations and their associations with metabolic factors were investigated in severely obese patients who underwent biliopancreatic diversion with duodenal switch (BPD/DS) and severely obese controls (SOC).



Sixty severely obese patients who underwent BPD/DS and 15 SOC (matched for BMI and age) were included in the study. Associations between nesfatin-1 levels and body composition, glucose metabolism, lipid profile as well as inflammatory markers were evaluated at baseline and over a post-surgery12-month (12M) period.



Body weight was reduced at 6M and at 12M in BPD/DS patients (P<0.001). Nesfatin-1 levels were reduced at 6M (women: P<0.05) and at 12M (men and women; P<0.001) in BPD/DS patients. At baseline, nesfatin-1 levels negatively correlated with weight, fat (FM) and fat-free mass (FFM) in the whole population (combined BPD/DS and SOC patients). At 12M, nesfatin-1 concentrations positively correlated with weight, FM, fasting insulin, insulin resistance, total cholesterol, LDL-cholesterol, triglyceride and apoB values. At 12M, % changes in nesfatin-1 were positively associated with% changes in weight, FM, FFM, fasting insulin, insulin resistance, total cholesterol, LDL-cholesterol, apoB and C-reactive protein.



Nesfatin-1 levels decrease following BPD/DS-induced weight loss and are significantly associated with parameters of metabolic health.
Centre de Recherche du CHU Sainte-Justine, Montréal, Québec, Canada; Département des Sciences de l'Activité Physique, Université du Québec à Montréal, Montréal, Québec, Canada.
David H
DH
St-Pierre
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada; Faculty of Pharmacy, Université Laval, Québec, Québec, Canada.
Julie
J
Martin
Faculty of Health Science, Kiryu University, Midori, Gunma, Japan.
Hiroyuki
H
Shimizu
Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Yuko
Y
Tagaya
Faculty of Pharmacy, Université Laval, Québec, Québec, Canada.
Takahumi
T
Tsuchiya
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada; Faculty of Medicine, Université Laval, Québec, Québec, Canada.
Simon
S
Marceau
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada; Faculty of Medicine, Université Laval, Québec, Québec, Canada.
Laurent
L
Biertho
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada; Faculty of Pharmacy, Université Laval, Québec, Québec, Canada.
Marjorie
M
Bastien
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada; Faculty of Pharmacy, Université Laval, Québec, Québec, Canada.
Sarah-Maude
SM
Caron-Cantin
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada.
Serge
S
Simard
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada; Faculty of Medicine, Université Laval, Québec, Québec, Canada.
Denis
D
Richard
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada; Faculty of Medicine, Université Laval, Québec, Québec, Canada.
Katherine
K
Cianflone
Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval, Québec, Québec, Canada; Faculty of Pharmacy, Université Laval, Québec, Québec, Canada. Electronic address: paul.poirier@criucpq.ulaval.ca.
Paul
P
Poirier
D000328:Adult; D050110:Bariatric Surgery; D015904:Biliopancreatic Diversion; D002135:Calcium-Binding Proteins / Q000097:blood*; D016022:Case-Control Studies; D004268:DNA-Binding Proteins / Q000097:blood*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009419:Nerve Tissue Proteins / Q000097:blood*; D000080866:Nucleobindins; D009767:Obesity, Morbid / Q000097:blood* / Q000473:pathology / Q000601:surgery; D016896:Treatment Outcome; D015431:Weight Loss
D002135:Calcium-Binding Proteins; D004268:DNA-Binding Proteins; C000630650:NUCB2 protein, human; D009419:Nerve Tissue Proteins; D000080866:Nucleobindins
Biliopancreatic diversion with duodenal switch; Cardiometabolic health; Nesfatin-1; Type 2 diabetes